A new study, conducted by researchers at the Perlmutter Cancer Center at New York University Langone Health in New York City, demonstrated how vitamin C might stop blood cancer stem cells from multiplying. That helps block some forms of leukemia from advancing.
Scientists discovered that intravenous treatment with vitamin C promoted DNA demethylation, making cancer stem cells to mature and die. This treatment also stopped blood cancer stem cells that were transplanted from human patients to mice from growing.
Corresponding study author Benjamin Neel, Ph.D., director of the Perlmutter Cancer Center, says: “Our results suggest that high-dose vitamin C – and it’s important to note that this means disease that has to be administered [intravenously] – might have therapeutic benefit in TET2-mutant myelodysplastic syndrome, either alone or in combination with current demethylating therapies and/or PARP inhibitors.”